

Triazolopyridines. Part 25: Synthesis of new chiral ligands from [1,2,3]triazolo[1,5-*a*]pyridines[☆]

Belén Abarca,^{a,*} Rafael Ballesteros,^a Rafael Ballesteros-Garrido,^{a,b}
Françoise Colobert^{b,*} and Frédéric R. Leroux^b

^a*Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Valencia, Avda. Vicente Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain*

^b*Laboratoire de stéréochimie associé au CNRS, Université Louis Pasteur (ECPM), 25 rue Becquerel, 67089 Strasbourg, France*

Received 4 July 2007; revised 20 July 2007; accepted 23 July 2007
Available online 2 August 2007

Abstract—The synthesis of new chiral triazolopyridine ligands possessing fluorescent properties is described. The triazolo ring opening was studied in order to obtain new chiral 2,6-disubstituted pyridines. A preliminary coordination assay with Zn(II) is also presented.
© 2007 Elsevier Ltd. All rights reserved.



1. Introduction

The pyridine ring can be found as structural motif in a large number of chiral ligands used in asymmetric catalysis,² and molecular recognition chemistry.³ Pyridines and 2,2'-bipyridines are common donor ligands.⁴ Jones and some of us have reported on the synthesis of interesting 2,6-disubstituted pyridines⁵ and bipyridines,⁶ using [1,2,3]triazolo[1,5-*a*]pyridines as synthons. We have also reported many aspects of the chemistry of [1,2,3]triazolo[1,5-*a*]pyridines,⁷ their fluorescent behaviour,⁸ application in the field of magnetic materials^{9,10} and in the preparation of fluorescent sensors.¹¹ However, there are no studies dealing with the preparation of chiral triazolopyridines. Due to our interest in the chemistry of triazolopyridines, we have now prepared new chiral compounds possessing fluorescent properties. The triazolo ring opening reaction affording chiral 2,6-disubstituted pyridines has also been studied as well as a preliminary coordination assay with Zn(II).

2. Results and discussion

We had reported that the regioselective metalation of [1,2,3]triazolo[1,5-*a*]pyridines (**1a** and **b**) with *n*-BuLi in toluene at -40 °C gives the 7-lithioderivatives **2a** and **b**, which react subsequently with a number of electrophiles to give 7-substituted triazolopyridines from **2a**.^{5,6b} However,

starting with **2b** the unexpected reaction products reveal an interesting structural feature. By an experimental (¹H NMR) and theoretical (DFT) studies,^{1,12} we have demonstrated that there is a ring-chain-ring isomerization of 3-(2-pyridyl)-[1,2,3]triazolo[1,5-*a*]pyrid-7-yl derivatives (**A**) into 6-[[1,2,3]triazolo[1,5-*a*]pyrid-3-yl]-2-pyridyl derivatives (**B**). The **A/B** ratio depends on the electronic properties of the substituent in the 7-position (**Scheme 1**). Electron-donating substituents favour the **A** form, electron-withdrawing substituents the **B** form, and only in the case where the substituent is a methyl group both forms are present (75% of **A** and 25% of **B**).



Scheme 1.


Using this methodology and with chiral electrophiles such as (-)-fenchone or (*R*)-(+)-menthyl-*p*-toluenesulfinate, we

[☆] See Ref. 1.

Keywords: *N*-Heterocycles; Triazolopyridines; Chiral fluorescent ligands.

* Corresponding authors. Tel.: +34963544933; fax: +34963544939; e-mail: belen.abarca@uv.es

have now obtained the corresponding chiral alcohols **3** (80%) and **4** (in **B** form, evidenced by ^1H , ^{13}C NMR and COSY experiments) (88%) as well as the chiral sulfoxides **5** and **6** (also in **B** form) (Scheme 2).




Scheme 2.

The alcohols **3** and **4** were formed as optically pure diastereomers, as was evidenced by ^1H NMR analysis. The preferential nucleophilic attack of 7-lithiotriazolopyridine to the carbonyl group of fenchone from the sterically less hindered side occurs according to the Felkin–Ahn model.¹³

Although chiral sulfoxides are very important compounds for asymmetric synthesis¹⁴ and asymmetric catalysis,¹⁵ the synthesis of enantiomerically pure triazolopyridine sulfoxides was so far unknown. Quéguiner et al.¹⁶ had shown that sulfoxides of π -deficient heterocycles can be obtained with excellent enantiomeric excesses by the Andersen method,¹⁷ using organometallic intermediates and chiral menthyl-*p*-toluenesulfonates as electrophiles. We have studied the reaction of 7-lithio-triazolopyridines **2a** and **b** with (*R*)-(+)-menthyl-*p*-toluenesulfonate, employing either normal or reverse addition at -40°C under different concentrations using toluene or tetrahydrofuran as solvent. The best conditions (see Experimental 3), afforded **5** and **6** in a low yield of 20% and 16%, respectively, with 97% ee (determined by HPLC). Concomitant formation of the dimerized compounds **7** (56%) and **8** (26%) was observed. Previously **7**^{6a} and **8**¹ were obtained in lower yields as secondary compounds in lithiation reactions. In our opinion the higher yield of dimerized side-products is due to a higher reactivity of in situ generated sulfoxide, which reacts with the lithiated intermediates **2a** and **b** by nucleophilic substitution. This reactivity pattern is well established in pyridine chemistry (Scheme 3).¹⁸

We had demonstrated that the conjugation of a triazolopyridine group with an aryl or heteroaryl group gives highly efficient fluorescent compounds.⁸ Derivatives **4** and **6** are new examples of fluorescent triazolopyridines. The alcohol **4** emitted at 409 nm and sulfoxide **6** at 387 nm and 404 nm when excited at 331 nm in CHCl_3 solution.

Another interesting application of triazolopyridines is their capacity to coordinate with metals, and behave as chemosensors for metal ions or anionic species.¹¹ The Zn^{2+} ion is an essential component of many enzymes, and plays an important role in maintaining the key structural features of gene



Scheme 3.


transcription proteins.¹⁹ Also, the role of Zn^{2+} in neurobiology has received significant attention.²⁰ In this regard, we are interested to develop chemosensors for Zn^{2+} ions. In a preliminary study, we have used the alcohol **4** to obtain a $\text{Zn}(\text{II})$ complex by reaction with zinc chloride. FABMS supports the formation of 1:1 $[\text{Zn}(\mathbf{4})]^{2+}-\text{Cl}_2$ aggregate. The emissive property of the complex presents a bathochromic shift of the fluorescence emission at 392 nm and 398 nm (λ^{exc} 331 nm), which appears at 409 nm. Encouraged by our preliminary results, we presently investigate the optical properties of these new chiral ligands.

3-Substituted-[1,2,3]triazolo[1,5-*a*]pyridines react with electrophiles by a triazole ring opening reaction with loss of nitrogen yielding 2,6-disubstituted pyridines.²¹ We have studied now the triazole ring opening reaction of the chiral alcohols **3** and **4** with the aim to obtain chiral 2,6-disubstituted pyridines. The reactions were performed with acetic acid, 2.5 M sulfuric acid and selenium dioxide as electrophiles.


Treatment of compound **3** with aqueous sulfuric acid gave the alcohol **9** (60%) as a diastereoisomeric mixture, de 5% (determined by NMR), and with acetic acid, the acetate **11** (75%, de 5%) was obtained. The chiral fenchyl group is too far from the triazolopyridine 3-position for chiral induction. In both cases small quantities of the elimination product, the vinylpyridine **10**, was formed. Under the usual conditions for treatment with selenium dioxide (i.e., 2.5 M sulfuric acid, 80°C , 24 h)^{21b} no reaction was observed. However, in *p*-xylene at reflux temperature, the known pyridine **12**²² was obtained, probably due to a total oxidation followed by decarboxylation of compound **13** (Scheme 4).

The alcohol **4** is more stable and does not react with sulfuric acid, acetic acid or selenium dioxide under the conditions described for reaction with **3**. When **4** was treated with acetic acid at reflux a diastereoisomeric mixture (de 3.5%) of acetates **14** was obtained in 42% yield (Scheme 5).

According to our hypothesis, the unusual stability of the alcohol **4** can be explained by an intramolecular hydrogen bond between the hydroxyl group and the lone pairs of the pyridine and N3-triazole nitrogen atoms (in analogy to a



Scheme 4.



Scheme 5.

proton sponge).²³ This hypothesis was supported by the treatment of ether **15** with acetic acid at reflux. In this case, the corresponding diastereoisomeric mixture (de 4%) of acetates **16** (26%) and ketones **17** (60%) was obtained. Thermal decomposition of diarylmethyl acetates to form ketones has been reported.²⁴ Reaction with sulfuric acid gave two ketone products, **17** (38%) as major product (probably obtained by oxidation of the initial alcohol intermediate) and the amazing cyclofenchone **18** (13%). The formation of **18** can be explained by the formation, in acid media, of a norbornyl cation as has been reported by Vonwiller²⁵ in fenchyl chemistry. The new chiral dipyrindyl ketones **17** and **18** could be very interesting compounds as building block in cluster chemistry.²⁶ This possibility is currently under investigation.

3. Experimental

3.1. General

Melting points were determined on a Kofler heated stage and are uncorrected. NMR spectra were recorded on a Bruker

AC300 MHz in CDCl_3 as solvent. COSY experiments were done for all compounds. HRMS (EI) determinations were made using a VG Autospec Trio 1000 (Fisons). Ultraviolet spectra were recorded on a Shimadzu UV-2101 instrument. Fluorescence spectra were recorded on a Spectrofluorimeter P.T.I. (Photon Technology International) instrument. Optical rotation measurements were determined on a Perkin-Elmer 241 polarimeter at room temperature in CHCl_3 solution. HPLC determinations were done in a Waters HPLC system with Mallinkrodt-Baker Chiralcel OD-H column. All the lithiation reactions were done under inert atmosphere and dry solvents.²⁷

*3-Methyl-[1,2,3]triazolo[1,5-*a*]pyridine 1a and 3-(2-pyridyl)-[1,2,3]triazolo[1,5-*a*]pyridine 1b* were prepared as described elsewhere.^{28–30,6b}

3.2. General procedure for lithiation of [1,2,3]triazolo[1,5-*a*]pyridines **1a** and **b**

To a solution of the corresponding [1,2,3]triazolo[1,5-*a*]pyridines **1a** and **b** (1 equiv) in anhydrous toluene at -40°C ,

a solution of *n*-butyllithium in hexane (2.5 M) (1.1 equiv) was added with stirring. A deep red colour developed. The mixture was kept at -40°C (15 min).

3.3. Reaction with (–)-fenchone

The corresponding mixture was treated with a dry toluene solution (10 mL) of (–)-fenchone (excess) recently distilled. Then was left at -40°C (2 h) and allowed at room temperature overnight, a colour change to yellow was observed. Then was treated with a saturated solution of ammonium chloride (15 mL). The organic layer was separated and the aqueous layer extracted with dichloromethane (3×20 mL). After drying over anhydrous Na_2SO_4 and evaporation of the organic solvents, a residue was obtained. The crude product was washed with hexane and filtered. Purification by recrystallization from ethyl acetate/hexane gave compounds **3** or **4** as white solids. The amount of reactants and yields are given for each compound.

3.3.1. (1*R*,2*S*,4*S*)-1,3,3-Trimethyl-2-[7'-(3'-methyl[1,2,3]triazolo[1,5-*a*]pyridyl)]bicyclo[2.2.1]hept-2-ol **3.** Compound **1a** (2 g, 15.03 mmol), toluene (120 mL), *n*-BuLi (6.6 mL), (–)-fenchone (5 g). Compound **3** (3.8 g, 88%) was obtained as a white solid. Mp 113°C (AcOEt/Hex 1:7). $[\alpha]_{\text{D}}^{20} -144.6$ (*c* 1.2, CHCl_3). HRMS found for M^+ 285.1824; $\text{C}_{17}\text{H}_{23}\text{N}_3\text{O}$ requires 285.1841. $^1\text{H NMR}$ δ 7.44 (dd, $J_1=7.8$ Hz, $J_2=1.8$ Hz, 1H), 7.14 (dd, $J_1=7.8$ Hz, $J_2=7.2$ Hz, 1H), 7.10 (dd, $J_1=7.2$ Hz, $J_2=1.8$ Hz, 1H), 6.67 (s, 1OH), 2.53–2.50 (m, 1H), 2.18 (dd, $J_1=10.5$ Hz, $J_2=2.1$ Hz, 1H), 1.78–1.67 (m, 2H), 1.45–1.29 (m, 2H), 1.31 (s, 3H), 1.26 (s, 3H), 1.15 (ddd, $J_1=12.6$ Hz, $J_2=12.6$ Hz, $J_3=3.9$ Hz, 1H), 0.24 (s, 3H). $^{13}\text{C NMR}$ δ 141.16 (C), 133.83 (C), 132.74 (C), 123.60 (CH), 115.02 (C), 114.26 (CH), 83.62 (C), 51.86 (C), 48.87 (CH), 45.97 (C), 42.00 (CH_2), 35.52 (CH_2), 26.94 (CH_2), 24.64 (CH_3), 22.82 (CH_3), 18.14 (CH_3), 10.27 (CH_3). UV λ_{max} (log ϵ) (CHCl_3) 294 (4.89), 312 (4.72). EM (EI) *m/z* (%) 285 (50), 257 (58), 242 (23), 229 (50), 214 (28), 174 (41), 160 (55), 105 (62), 104 (100).

3.3.2. (1*R*,2*S*,4*S*)-1,3,3-Trimethyl-2-(6-[1,2,3]triazolo[1,5-*a*]pyridin-3-yl-pyridin-2-yl)-bicyclo[2.2.1]hept-2-ol **4.** Compound **1b** (1.07 g, 8.7 mmol), toluene (80 mL), *n*-BuLi (4 mL), (–)-fenchone (4 g). Compound **4** (2.46 g, 80%) was obtained as a white solid. Mp $144\text{--}146^{\circ}\text{C}$ (AcOEt/Hex 1:7). $[\alpha]_{\text{D}}^{20} -69$ (*c* 0.66, CHCl_3). HRMS found for M^+ 348.1915; $\text{C}_{21}\text{H}_{24}\text{N}_4\text{O}$ requires 348.1950. $^1\text{H NMR}$ δ 8.70 (d, $J=6.9$ Hz, 1H), 8.34 (d, $J=7.9$ Hz, 1H), 8.16 (d, $J=8.3$ Hz, 1H), 7.72 (dd, $J_1=J_2=7.9$ Hz, 1H), 7.40 (d, $J=7.9$ Hz, 1H), 7.32 (dd, $J_1=6.9$ Hz, $J_2=8.3$ Hz, 1H), 6.99 (dd, $J_1=J_2=6.9$ Hz, 1H), 5.89 (br s, 1OH), 2.35–2.15 (m, 2H), 1.90–1.75 (m, 1H), 1.50–1.41 (m, 1H), 1.33 (d, $J=10.5$ Hz, 1H), 1.20–1.18 (m, 1H), 1.00 (s, 6H), 0.82 (m, 1H), 0.45 (s, 3H). $^{13}\text{C NMR}$ δ 161.55 (C), 149.09 (C), 136.98 (C), 136.16 (CH), 131.56 (C), 126.80 (CH), 125.47 (CH), 121.56 (CH), 120.09 (CH), 118.54 (CH), 115.77 (CH), 84.07 (C), 55.77 (C), 48.81 (CH), 46.02 (C), 41.89 (CH_2), 32.61 (CH_2), 26.28 (CH_3), 24.27 (CH_2), 21.64 (CH_3), 17.14 (CH_3). UV λ_{max} (log ϵ) (CHCl_3) 290 (4.75), 313 (4.93), 324 (4.92). EM (EI): *m/z* (%) 348 (25), 320 (30), 292 (100), 169 (80).

3.4. Reaction with (R)-(+)-menthyl-*p*-toluenesulfinate

The lithiated triazolopyridines **2a** and **b** were poured by double-needle over a solution of (R)-(+)-menthyl-*p*-toluenesulfinate (1.5 equiv) in dry toluene (1.5 mL). The mixture was left at -40°C (2 h) and allowed at room temperature overnight, a colour change to yellow was observed. Then it was treated with a saturated solution of ammonium chloride (15 mL). The organic layer was separated and the aqueous layer extracted with dichloromethane (3×20 mL). After drying over anhydrous Na_2SO_4 and evaporation of the organic solvents, a residue was obtained. The residue was purified by chromatotron using hexane/ethyl acetate as eluent, starting material and menthol were obtained in the first fractions. The amount of reactants and yields are given for each compound.

3.4.1. (R)-3-Methyl-7-(toluene-4-sulfinyl)-[1,2,3]triazolo[1,5-*a*]pyridine **5.** Compound **1a** (153 mg, 1.15 mmol), toluene (10 mL), *n*-BuLi (0.5 mL) and (R)-(+)-menthyl-*p*-toluenesulfinate (490 mg). Compound **5** (60.5 mg, 20%) was obtained as a white solid. Mp 145°C (AcOEt/Hex 1:7). $[\alpha]_{\text{D}}^{20} +281.6$ (*c* 0.39, CHCl_3). HRMS found for M^+ 271.0778; $\text{C}_{14}\text{H}_{13}\text{N}_3\text{OS}$ requires 271.0779. $^1\text{H NMR}$ δ 7.89 (d, $J=8.2$ Hz, 2H), 7.71 (dd, $J_1=6.9$ Hz, $J_2=1$ Hz, 1H), 7.65 (dd, $J_1=8.9$ Hz, $J_2=1$ Hz, 1H), 7.38 (dd, $J_1=8.9$ Hz, $J_2=6.9$ Hz, 1H), 7.22 (d, $J=8.2$ Hz, 2H), 2.58 (s, 3H), 2.30 (s, 3H). $^{13}\text{C NMR}$ δ 143.04 (C), 141.29 (C), 137.84 (C), 135.19 (C), 132.08 (CH), 129.92 (C), 126.28 (CH), 123.88 (CH), 118.88 (CH), 111.68 (CH), 21.47 (CH_3), 10.35 (CH_3). EM (EI) *m/z* (%) 273 (3), 271 (40), 243 (63), 226 (35), 195 (30), 139 (100), 120 (36), 104 (60), 91 (42), 77 (67). 7,7'-Bis(3-methyl[1,2,3]triazolo[1,5-*a*]pyridine) **7** (81 mg, 56%) was obtained as a fluorescent yellow solid mp $238\text{--}240^{\circ}\text{C}$.^{6a}

3.4.2. (R)-3-[6-(Toluene-4-sulfinyl)-pyridin-2-yl]-[1,2,3]triazolo[1,5-*a*]pyridine **6.** Compound **1b** (153 mg, 0.79 mmol), toluene (10 mL), *n*-BuLi (0.34 mL) and (R)-(+)-menthyl-*p*-toluenesulfinate (345 mg). Compound **6** (41 mg, 15%) was obtained as a white solid. Mp $167\text{--}170^{\circ}\text{C}$ (AcOEt/Hex 1:7). $[\alpha]_{\text{D}}^{20} +15.5$ (*c* 1.2, CHCl_3). HRMS found for M^+ 334.0904; $\text{C}_{18}\text{H}_{14}\text{N}_4\text{OS}$ requires 334.0888. $^1\text{H NMR}$ δ 8.69 (d, $J=7.0$ Hz, 1H), 8.37 (d, $J=8.9$ Hz, 1H), 8.27 (dd, $J_1=7.2$ Hz, $J_2=1.8$ Hz, 1H), 7.91 (dd, $J_1=7.1$ Hz, $J_2=7.8$ Hz, 1H), 7.88 (dd, $J_1=7.8$ Hz, $J_2=1.8$ Hz, 1H), 7.65 (d, $J=8.1$ Hz, 2H), 7.33 (dd, $J_1=7.0$ Hz, $J_2=8.9$ Hz, 1H), 7.2 (d, $J=8.1$ Hz, 2H), 7.0 (dd, $J_1=7.0$ Hz, $J_2=6.9$ Hz, 1H), 2.30 (s, 3H). $^{13}\text{C NMR}$ δ 165.00 (C), 152.40 (C), 141.90 (C), 141.26 (C), 138.67 (CH), 136.16 (C), 132.19 (C), 129.93 (CH), 126.96 (CH), 125.42 (CH), 125.35 (CH), 121.19 (CH), 120.84 (CH), 116.74 (CH), 116.05 (CH), 21.82 (CH_3). UV λ_{max} (log ϵ) (CHCl_3) 240 (4.45), 275 (4.42), 331 (4.46). EM (EI) *m/z* (%) 336 (3), 334 (40), 306 (75), 258 (65), 215 (10), 199 (5), 183 (86), 167 (100), 139 (80), 113 (20), 91 (44), 78 (47). 7,7'-Bis(3-(2-pyridyl)-[1,2,3]triazolo[1,5-*a*]pyridine) **8** (80 mg, 26%) was obtained as a fluorescent yellow solid mp $>300^{\circ}\text{C}$.¹

3.5. (1*R*,2*S*,4*S*)-3-[6-(2-Methoxy-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl)pyridin-2-yl]-[1,2,3]triazolo[1,5-*a*]pyridine **15**

To a stirred solution of 2-[6-([1,2,3]triazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl]-1,3,3-trimethylbicyclo[2.2.1]heptan-2-ol **4**

(348 mg, 1 mmol, 1 equiv) in THF (11 mL), NaH (100 mg, 4.10 mmol, 4.10 equiv) was added at 25 °C. After being stirred for 30 min, iodomethane (0.569 g, 4.00 mmol, 0.56 mL) was added, and the resulting mixture was stirred for 16 h at 25 °C, monitored by TLC. Then saturated aqueous NH₄Cl (5 mL) solution was added to quench the reaction, the resulting mixture was extracted with CH₂Cl₂ (3×50 mL). The organic extracts were combined, washed with brine, dried over Na₂SO₄, filtered and concentrated. Column chromatography (silica, ethyl acetate/cyclohexane gradient) provided 0.343 mg (95%) of **15** as a white solid. Mp 127–130 °C. [α]_D²⁰ 7.7 (*c* 1, CHCl₃). HRMS found for M⁺ 362.2096; C₂₂H₂₆N₄O requires 362.2107. ¹H NMR δ 8.81 (d, *J*=9.07 Hz, 1H), 8.76 (d, *J*=6.98 Hz, 1H), 8.26 (d, *J*=7.80 Hz, 1H), 7.75 (dd, *J*₁=*J*₂=7.90 Hz, 1H), 7.41 (d, *J*=7.93 Hz, 1H), 7.35 (dd, *J*₁=6.60 Hz, *J*₂=8.90 Hz, 1H), 7.03 (dd, *J*₁=*J*₂=6.64 Hz, 1H), 3.23 (s, 3H), 3.05 (d, *J*=8.61 Hz, 1H), 2.15 (m, 1H), 2.89 (m, 1H), 1.7 (d, *J*=4.21 Hz, 1H), 1.5 (m, 2H), 1.31 (m, 2H), 1.04 (s, 3H), 0.38 (s, 3H). ¹³C NMR δ 162.4 (C), 149.8 (C), 138.2 (C), 136.1 (CH), 131.5 (C), 125.9 (CH), 125.3 (CH), 121.8 (CH), 121.0 (CH), 117.8 (CH), 115.6 (CH), 90.0 (C), 54.7 (OCH₃), 52.3 (C), 48.8 (CH), 48.5 (C), 44.4 (CH₂), 32.2 (CH₂), 29.1 (CH₃), 25.1 (CH₂), 21.6 (CH₃), 20.7 (CH₃). EM (EI) *m/z* (%) 362 (27), 347 (64), 319 (64), 281 (36), 221 (50), 195 (24), 168 (75), 167 (38), 81 (100), 78 (65).

3.6. General procedure for ring opening reactions of triazolopyridines **3**, **4** and **15** with AcOH

A solution of the corresponding triazolopyridine in glacial acetic acid (10 mL) was heated (see conditions in Table 1). The solution was neutralized with saturated aqueous solution of sodium bicarbonate and extracted with dichloromethane. The organic solvent was dried and evaporated. The residue was purified by silica column chromatography or chromatotron. The products, yields and conditions of purification are given for each compound.

3.6.1. 1-[6-(2-Hydroxy-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl)pyridin-2-yl] ethyl acetate **11.** Diastereomeric mixture, 5% de (1*R*,2*S*,4*S*,1'*S*) and (1*R*,2*S*,4*S*,1'*R*). Purified by chromatotron with ethyl acetate/hexane (132 mg, 75%, colourless oil). HRMS found for M⁺ 317.1986; C₁₉H₂₇N₃O requires 317.1990. ¹H NMR δ 7.62 (dd, *J*₁=7.8 Hz, *J*₂=7.5 Hz, 2H), 7.40 (d, *J*=7.8 Hz, 1H), 7.41 (d, *J*=7.8 Hz, 1H), 7.17 (d, *J*=7.5 Hz, 1H), 7.16 (d, *J*=7.5 Hz, 1H), 5.92–5.84 (m, 2H), 2.35–2.20 (br m, 2H), 2.11 (s, 3H), 2.10 (s, 3H), 1.90–1.7 (m, 4H), 1.55 (d, *J*=6.6 Hz, 6H), 1.51–1.41

(m, 2H), 1.33 (d, *J*=10.2 Hz, 2H), 1.13 (ddd, *J*₁=*J*₂=12.3 Hz, *J*₃=4.5 Hz, 2H), 0.99 (s, 3H), 0.98 (s, 3H), 0.97 (s, 3H), 0.95 (s, 3H), 0.38 (s, 3H), 0.35 (s, 3H). ¹³C NMR δ 170.22/170.14 (C), 161.84/161.82 (C), 157.34/157.25 (C), 135.88/135.57 (CH), 121.75/121.63 (CH), 117.73/117.63 (CH), 83.56 (C), 72.55/72.49 (C), 51.62/51.57 (CH), 48.76 (CH), 45.92 (C), 41.84/41.73 (CH₃), 32.43/32.31 (CH₂), 29.09 (CH₂), 24.36/24.22 (CH₂), 22.13 (CH), 21.19/21.15 (CH₃), 20.84/20.48 (CH₃), 20.36/20.22 (CH₃), 17.11/17.08 (CH₃). EM (EI) *m/z* (%) 317 (10), 236 (85), 176 (20), 81 (100).

3.6.2. (1*R*,2*S*,4*S*)-1,3,3-Trimethyl-2-(6-vinylpyridin-2-yl)-bicyclo[2.2.1]hept-2-ol **10.** Purified by chromatotron with ethyl acetate/hexane (15 mg, 17% oil colourless). HRMS found for M⁺ 257.1779; C₁₇H₂₃NO₂ requires 257.1779. ¹H NMR δ 7.60 (dd, *J*₁=7.8 Hz, *J*₂=7.5 Hz, 1H), 7.39 (d, *J*=7.8 Hz, 1H), 7.16 (d, *J*=7.5 Hz, 1H), 6.76 (dd, *J*₁=17.4 Hz, *J*₂=12 Hz, 1H), 6.20 (dd, *J*₁=17.4 Hz, *J*₂=1.5 Hz, 1H), 5.45 (dd, *J*₁=12 Hz, *J*₂=14.5 Hz, 1H), 2.32–2.15 (m, 2H), 1.87–1.7(m, 2H), 1.5–1.37 (m, 1H), 1.29 (dd, *J*₁=1.5 Hz, *J*₂=12 Hz, 1H), 1.18 (br s, 1OH), 1.06 (ddd, *J*₁=*J*₂=12.6 Hz, *J*₃=4.8 Hz, 2H), 0.92 (s, 3H), 0.90 (s, 6H), 0.39 (s, 3H). ¹³C NMR δ 152.56 (C), 152.41 (C), 136.30 (CH), 135.64 (CH), 122.01 (CH), 119.07 (CH), 118.00 (CH₂), 83.528 (C), 48.80 (CH), 45.96 (C), 42.01 (CH₂), 32.52 (CH₂), 29.69 (C), 29.29 (CH), 24.38 (CH₂), 24.41 (CH₃), 22.28 (CH₃), 17.17 (CH₃). EM (EI) *m/z* (%) 257 (15), 242 (15), 229 (35), 176 (100), 160 (82), 153 (12), 104 (45), 81 (60), 77 (18).

3.6.3. [6-(2-Hydroxy-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl)pyridin-2-yl](pyridin-2-yl) methyl acetate **14.** Diastereomeric mixture 3.5% de (1*R*,2*S*,4*S*,1'*S*) and (1*R*,2*S*,4*S*,1'*R*). Silica column chromatography eluted with ethyl acetate/cyclohexane (91.1 mg, 42%, colourless oil). HRMS found 380.2108 for M⁺; C₂₃H₂₈N₂O₃ requires 380.2100. ¹H NMR δ 8.53 (m, 2H), 7.67 (m, 4H), 7.51 (dd, *J*₁=*J*₂=8.0 Hz, 2H), 7.40 (m, 4H), 7.18 (m, 2H), 6.87 (s, 1H), 6.85 (s, 1H), 2.21 (s, 3H), 2.20 (s, 3H), 1.82–1.72 (m, 4H), 1.43 (m, 2H), 1.28 (m, 2H), 1.10 (m, 2H), 0.95 (s, 3H), 0.93 (s, 3H), 0.85 (s, 3H), 0.82 (s, 3H), 0.26 (s, 3H), 0.23 (s, 3H). ¹³C NMR δ 169.9/169.9 (C), 157.9 (C), 155.0/154.9 (C), 149.3/149.2 (CH), 136.6 (CH), 136.1 (CH), 122.9/122.8 (CH), 122.5/122.2 (CH), 121.9/121.7 (CH), 119.8/119.2 (CH), 83.7 (C), 78.2 (CH), 48.1 (CH), 46.0/45.9 (C), 41.8 (CH₃), 32.5/32.4 (CH₂), 28.8/28.7 (CH₃), 24.3 (CH₂), 22.0/21.9 (CH₃), 21.1/21.0 (CH₃), 17.1/17.0 (CH). EM (EI) *m/z* (%) 380 (7), 321 (27), 320 (100), 299 (30), 292 (31), 283 (30).

Table 1

Starting material (mg, mmol)	Reactant/solvent	<i>t</i> (h)/ <i>T</i> (°C)	Product (mg, %)
3 (102, 0.35)	H ₂ SO ₄ /H ₂ O	23/100	9 (52, 60); 10 (10, 10)
3 (160, 0.56)	AcOH	5/80	11 (132, 75); 10 (15, 17)
3 (100, 0.35)	SeO ₂ /H ₂ SO ₄	24/80	No reaction
3 (100, 0.35)	SeO ₂ / <i>p</i> -xylene	72/140	12 (18, 22)
4 (109, 0.30)	H ₂ SO ₄ /H ₂ O	24/100	No reaction
4 (110, 0.31)	AcOH	24/80	No reaction
4 (197, 0.57)	AcOH	6/115	14 (91, 42)
4 (100, 0.29)	SeO ₂ /H ₂ SO ₄	24/100	No reaction
15 (150, 0.42)	H ₂ SO ₄ /H ₂ O	24/100	18 (17, 13); 17 (55, 38)
15 (148, 0.40)	AcOH	50/115	16 (40, 26); 17 (83, 60)

3.6.4. [6-(2-Methoxy-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl)pyridin-2-yl](pyridin-2-yl) methyl acetate 16. Diastereomeric mixture, 4% de (1*R*,2*S*,4*S*,1'*S*) and (1*R*,2*S*,4*S*,1'*R*). Silica column chromatography eluted with ethyl acetate/cyclohexane (40 mg, 26%, yellow oil). HRMS found 394.2254 for M⁺; C₂₄H₃₀N₂O₃ requires 394.2256. ¹H NMR δ 8.54 (m, 2H), 7.69 (ddd, J₁=J₂=7.71 Hz, J₃=1.75 Hz, 2H), 7.61 (dd, J₁=J₂=7.57 Hz, 2H), 7.57 (dd, J₁=J₂=8.80 Hz, 2H), 7.32 (dd, J₁=2.98 Hz, J₂=7.64 Hz, 2H), 7.28 (d, J=7.98 Hz, 2H), 7.17 (m, 2H), 6.91/6.89 (s, 2H), 3.12/3.11 (s, 6H), 2.51 (m, 2H), 2.21 (s, 6H), 2.05–1.96 (m, 2H), 1.83–1.73 (m, 2H), 1.54–1.36 (m, 4H), 1.18 (s, 3H), 1.15 (s, 3H), 1.12–1.07 (m, 2H), 1.00 (m, 2H), 0.92 (s, 6H), 0.08 (s, 3H), 0.05 (s, 3H). ¹³C NMR δ 170/169 (C), 162.3/162.2 (C), 158.5 (C), 155.6/155.5 (C), 149.9/149.0 (CH), 136.4 (CH), 136.0 (CH), 122.8/122.7 (CH), 122.7/122.5 (CH), 122.0/121.9 (CH), 118.9/118.7 (CH), 89.9 (C), 78.7/78.6 (CH), 54.6 (CH₃), 52.4/52.3 (C), 48.4/48.3 (C), 48.4 (CH₃), 44.3/44.2 (CH₂), 31.7 (CH₂), 28.8/28.7 (CH₃), 25.3 (CH₂), 21.2/21.1 (CH₃), 20.0/19.8 (CH₃), 14.1 (CH). EM (EI) *m/z* (%) 394 (16), 380 (30), 379 (100), 319 (31), 314, (20), 313 (96).

3.6.5. (1*R*,2*S*,4*S*)-[6-(2-Methoxy-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl)pyridin-2-yl](pyridin-2-yl) methanone 17. Silica column chromatography eluted with ethyl acetate/cyclohexane (83.1 mg, 60% colourless oil). HRMS found for M⁺ 350.1995; C₂₂H₂₆N₂O₂ requires 350.1994. ¹H NMR δ 8.68 (m, 1H), 7.95 (dd, J₁=7.62 Hz, J₂=1.09 Hz, 1H), 7.94–7.79 (m, 3H), 7.06 (dd, J₁=7.99 Hz, J₂=1.10 Hz, 1H), 7.44–7.40 (m, 1H), 3.15 (s, 3H), 2.31 (m, 1H), 2.01 (m, 1H), 1.83–1.73 (m, 1H), 1.54–1.36 (m, 3H), 1.18 (s, 3H), 1.14–1.04 (m, 1H), 0.98 (s, 3H), 0.30 (s, 3H). ¹³C NMR δ 194.4 (C=O), 162.2 (C), 155.8 (C), 152.5 (C), 148.9 (CH), 136.2 (CH), 136.1 (CH), 126.0 (CH), 125.3 (CH), 123.9 (CH), 121.6 (CH), 90.0 (C), 54.6 (CH₃), 52.2 (C), 48.5 (C), 48.4 (CH₃), 44.4 (CH₂), 31.6 (CH₂), 29.1 (CH₃), 24.4 (CH₂), 21.6 (CH₃), 19.9 (CH₃), 14.1 (CH). EM (EI) *m/z* (%) 350 (13), 335 (50), 269 (100), 78 (18).

3.7. General procedure for ring opening reactions of triazolopyridines 3, 4 and 15 with sulfuric acid

A solution of the corresponding triazolopyridine in aqueous sulfuric acid (10 mL, 2.5 M) was heated (see conditions in Table 1). The solution was neutralized with a saturated aqueous solution of sodium bicarbonate and extracted with dichloromethane. The organic solvent was dried and evaporated. The residue was purified by silica column chromatography or chromatotron. With 4 no reaction was observed. The products, yields and conditions of purification are given for each compound.

3.7.1. 2-[6-(1-Hydroxy-ethyl)-pyridin-2-yl]-1,3,3-trimethylbicyclo[2.2.1]hept-2-ol 9. Diastereomeric mixture 5% de (1*R*,2*S*,4*S*,1'*S*) and (1*R*,2*S*,4*S*,1'*R*). Purified by chromatotron with ethyl acetate/hexane (52 mg, 60% colourless oil). HRMS found for M⁺ 275.1889; C₁₇H₂₅NO₂ requires 275.1885. ¹H NMR δ 7.65 (dd, J₁=7.8 Hz, J₂=7.5 Hz, 2H), 7.43 (d, J=7.8 Hz, 2H), 7.18 (d, J=7.5 Hz, 2H), 4.88 (d, J=6.6 Hz, 2H), 3.2 (br s, 2OH), 2.28 (m, 4H), 1.87–1.78 (m, 4H), 1.5 (d, J=6.6 Hz, 3H), 1.49 (d, J=6.6 Hz, 3H), 1.51–1.48 (m, 2H), 1.35 (d, J=9.3 Hz, 2H), 1.17

(ddd, J₁=J₂=12.9 Hz, J₃=4.8 Hz, 2H), 1.00 (s, 3H), 0.99 (s, 3H), 0.98 (s, 6H), 0.40 (s, 3H), 0.39 (s, 3H). ¹³C NMR δ 162.11 (C), 161.19 (C), 136.62 (CH), 121.90/121.84 (CH), 117.71 (CH), 84.24 (C), 70.09/69.93 (CH), 52.45/52.36 (C), 49.24 (CH), 46.47 (C), 42.39 (CH₂), 32.92 (CH₂), 29.55/29.52 (CH), 24.80/24.68 (CH₂), 24.41 (CH₃), 22.55 (CH₃), 17.58 (CH₃). EM (EI) *m/z* (%) 275 (8), 260 (12), 194 (100), 178 (71). In the first fraction 10 (10 mg, 10%) was obtained.

3.7.2. Pyridin-2-yl [6-(2,7,7-trimethyltricyclo[2,2,1,0^{2,6}]hept-1-yl)pyridin-2-yl] methanone 18. Silica column chromatography with ethyl acetate/cyclohexane as eluent. Brown oil (17 mg, 13%). HRMS found for M⁺ 318.1733; C₂₁H₂₂N₂O requires 318.1732. ¹H NMR δ 8.73 (d, J=4.34 Hz, 1H), 8.06 (d, J=7.82 Hz, 1H), 7.90 (dd, J₁=7.67 Hz, J₂=0.98 Hz, 1H), 7.83 (ddd, J₁=J₂=7.71 Hz, J₃=1.7 Hz, 1H), 7.74 (dd, J₁=J₂=7.79 Hz, 1H), 7.43 (m, 1H), 7.35 (dd, J₁=7.86 Hz, J₂=1.00 Hz, 1H), 1.82 (m, 2H), 1.53 (m, 1H), 1.40 (s, 1H), 1.32 (m, 1H), 1.22 (m, 1H), 1.07 (s, 3H), 1.00 (s, 3H), 0.86 (s, 3H). ¹³C NMR δ 193.4 (C=O), 159.0 (C), 154.7 (C), 153.5 (C), 149.1 (CH), 136.0 (CH), 127.3 (CH), 127.2 (CH), 125.7 (CH), 125.6 (CH), 121.3 (CH), 46.8 (C), 44.1 (CH), 42.0 (C), 38.6 (CH₂), 32.2 (CH₂), 29.4 (C), 27.1 (CH₃), 22.6 (CH₃), 21.7 (CH₃), 14.0 (CH). EM (EI) *m/z* (%) 318 (100), 303 (60), 277 (34), 212 (20), 78 (20). Further elution gave 17 (55.1 g, 38%).

3.8. Ring opening reaction of triazolopyridines 3 and 4 with SeO₂

Method A: a suspension of triazolopyridine 3 or 4 and selenium dioxide (2 equiv) in sulfuric acid (10 mL, 2.5 M) was heated (see conditions in Table 1). *Method B:* a suspension of 3 and selenium dioxide (2 equiv) in *p*-xylene was heated (see conditions in Table 1). Then the corresponding mixture was filtered and the filtrate neutralized with a saturated aqueous solution of sodium hydrogencarbonate and extracted with dichloromethane. The organic solvent was dried and evaporated. The residue was purified by chromatotron to obtain 12 (22%).

3.9. Synthesis of Zn(4)Cl₂

To a solution of (1*R*,2*S*,4*S*)-1,3,3-trimethyl-2-(6-[1,2,3]triazolo[1,5-*a*]pyridin-3-yl-pyridin-2-yl)-bicyclo[2.2.1]hept-2-ol 4 (50 mg, 0.14 mmol) in dichloromethane (20 mL), a solution of Cl₂Zn in ether (0.15 mL, 1 M) was added. A yellow solution was formed and was stirred (30 min) at room temperature. Evaporation of the solvent gives a yellow oil that was washed with hot ethyl acetate. The oil obtained has identical ¹H and ¹³C NMR in DMSO-*d*₆ that the ligand 4. HRMS (FAB) found for M⁺ 447.093; C₂₁H₂₄N₄OClZn requires 447.093. MS *m/e* (%) 454 (3), 453 (16), 452 (17), 451 (62), 450 (31), 449 (92), 448 (25), 447 (100). UV λ_{max} (log ε) (MeOH) 225 (2.5), 270 (2.47), 311 (2.56), 320 (2.57).

Acknowledgements

We are much grateful to the Ministerio de Educación y Ciencia (Spain) (Project CTQ2006-15672-C05-03) for its financial support, and to the SCSIE for the realization of the

HRMS spectra. R.B.-G. wants to thank the Ministère de l'Éducation Nationale, de la Recherche et de la Technologie (France) for a predoctoral fellowship.

References and notes

1. Last part in the series: Abarca, B.; Ballesteros, R.; Chadlaoui, M. *Tetrahedron* **2004**, *60*, 5785–5792.
2. Chelucci, G. *Chem. Soc. Rev.* **2006**, *35*, 1230–1243 and references cited therein.
3. Lehn, J.-M. *Supramolecular Chemistry, Concepts and Perspectives*; VCH: Weinheim, 1995.
4. (a) Reedijk, J. *Comprehensive Coordination Chemistry*; Wilkinson, S. G., Ed.; Pergamon: London, 1987; Vol. 2; (b) Constable, E. C. *Metals and Ligand Reactivity*; VCH: Weinheim, 1996.
5. Jones, G.; Sliskovic, R. *J. Chem. Soc., Perkin Trans. 1* **1982**, 967–971.
6. (a) Jones, G.; Pitman, M. A.; Lunt, E.; Lyghgoe, D. J.; Abarca, B.; Ballesteros, R.; Elmasnouy, M. *Tetrahedron* **1997**, *53*, 8257–8268; (b) Abarca, B.; Ballesteros, R.; Elmasnouy, M. *Tetrahedron* **1998**, *54*, 15287–15292.
7. Abarca, B. *J. Enzyme Inhib. Med. Chem.* **2002**, *17*, 359–367 and references cited therein.
8. Abarca, B.; Aucejo, R.; Ballesteros, R.; Blanco, F.; García-España, E. *Tetrahedron Lett.* **2006**, *47*, 8101–8103.
9. Niel, V.; Gaspar, A. B.; Muñoz, M. C.; Abarca, B.; Ballesteros, R.; Real, J. A. *Inorg. Chem.* **2003**, *42*, 4782–4788.
10. Boudalis, A. K.; Raptoulo, C. P.; Abarca, B.; Ballesteros, R.; Chadlaoui, M.; Tuchagues, J.-P.; Terzis, A. *Angew. Chem., Int. Ed.* **2006**, *45*, 432–435.
11. Chadlaoui, M.; Abarca, B.; Ballesteros, R.; Ramírez de Arellano, C.; Aguilar, J.; Aucejo, R.; García-España, E. *J. Org. Chem.* **2006**, *71*, 9030–9034.
12. Abarca, B.; Alkorta, I.; Ballesteros, R.; Blanco, F.; Chadlaoui, M.; Elguero, J.; Mojarrad, F. *Org. Biomol. Chem.* **2005**, *3*, 3905–3910.
13. (a) Chérest, M.; Felkin, H.; Prudent, N. *Tetrahedron Lett.* **1968**, *9*, 2199–2204; (b) Ahn, N. T. *Top. Curr. Chem.* **1980**, *88*, 145–162.
14. Hanquet, G.; Colobert, F.; Lanners, S.; Solladié, G. *Arkivoc* **2003**, *7*, 328–401.
15. Pellissier, H. *Tetrahedron* **2007**, *63*, 1297–1330.
16. Pollet, P.; Turk, A.; Plé, N.; Quéguiner, G. *J. Org. Chem.* **1999**, *64*, 4512–4515.
17. Andersen, K. K.; Gaffield, W.; Papanikolaou, N. E.; Foley, J. W.; Perkins, R. I. *J. Am. Chem. Soc.* **1964**, *86*, 5637–5646.
18. (a) Kawai, T.; Furukawa, N.; Oae, S. *Tetrahedron Lett.* **1984**, *25*, 2549–2552; (b) Furukawa, N.; Shibutani, T.; Furihara, H. *Tetrahedron Lett.* **1987**, *28*, 5845–5848; (c) Vinishi, J.; Tanaka, T.; Wakabayashi, S.; Oae, S. *Tetrahedron Lett.* **1990**, *31*, 4625–4628; (d) Furukawa, N.; Ogawa, S.; Matsumura, K.; Furihara, Y. H. *J. Org. Chem.* **1991**, *56*, 6341–6348; (e) Shibutani, T.; Furihara, H.; Furukawa, N. *Tetrahedron Lett.* **1991**, *32*, 2947–2948.
19. (a) Vallee, B. L.; Falchuk, K. H. *Physiol. Rev.* **1993**, *73*, 79–188; (b) Berg, J. M.; Shi, Y. *Science* **1996**, *271*, 1081–1085.
20. Bush, A. I. *Curr. Opin. Chem. Biol.* **2000**, *4*, 184–191.
21. (a) Jones, G.; Sliskovic, R.; Foster, B.; Rogers, J.; Smith, A. K.; Wong, M. I.; Yarhan, A. C. *J. Chem. Soc., Perkin Trans. 1* **1981**, 78–81; (b) Jones, G.; Mouat, D. J.; Tonkinson, D. *J. Chem. Soc., Perkin Trans. 1* **1985**, 2719–2723; (c) Abarca, B.; Ballesteros, R.; Rodrigo, G.; Jones, G.; Veciana, J.; Vidal-Gancedo, J. *Tetrahedron* **1998**, *54*, 9785–9790.
22. Genov, M.; Kostova, K.; Dimitrov, V. *Tetrahedron: Asymmetry* **1997**, *8*, 1869–1876.
23. Staab, H. A.; Saupe, T. *Angew. Chem., Int. Ed. Engl.* **1988**, *27*, 865–879.
24. Pawel, J.; Serafinowski, M.; Garland, B. *J. Am. Chem. Soc.* **2003**, *125*, 962–965.
25. Scott, M.; Starling, S.; Vonwiller, C.; Joost, N.; Reek, H. *J. Org. Chem.* **1998**, *63*, 2262–2272.
26. (a) Papaefstathiou, G. S.; Perlepes, S. P. *Comments Inorg. Chem.* **2002**, *23*, 249–274; (b) Boudalis, A. K.; Donnadiou, B.; Nastopoulos, V.; Clemente-Juan, J. M.; Mari, A.; Sanakis, Y.; Tuchagues, J.-P.; Perlepes, S. P. *Angew. Chem.* **2004**, *116*, 2316–2320; *Angew. Chem., Int. Ed.* **2004**, *43*, 2266–2270; (c) Tsohos, A.; Dionyssopoulou, S.; Raptoupolou, C. P.; Terzis, A.; Bakalbassis, E. G.; Perlepes, S. P. *Angew. Chem.* **1999**, *111*, 1036–1038; *Angew. Chem., Int. Ed.* **1999**, *38*, 983–985; (d) Papaefstathiou, G. S.; Perlepes, S. P.; Escuer, A.; Vicente, R.; Font-Bardia, M.; Solans, X. *Angew. Chem.* **2001**, *113*, 908–910; *Angew. Chem., Int. Ed.* **2001**, *40*, 884–886; (e) Papaefstathiou, G. S.; Escuer, A.; Vicente, R.; Font-Bardia, M.; Solans, X.; Perlepes, S. P. *Chem. Commun.* **2001**, 2414–2415.
27. Perrin, D.; Armarego, L. F. *Purification of Laboratory Chemicals*, 3rd ed.; Pergamon: Oxford, 1988.
28. Boyer, J. H.; Borgers, R.; Wolford, L. T. *J. Am. Chem. Soc.* **1957**, *79*, 678–680.
29. Bower, J. D.; Ramage, G. R. *J. Chem. Soc.* **1957**, 4506–4510.
30. Battaglia, L. P.; Carcelli, M.; Ferraro, F.; Mavilla, L.; Pellizzi, C.; Pellizzi, G. *J. Chem. Soc., Dalton Trans.* **1994**, 2651–2654.